To include your compound in the COVID-19 Resource Center, submit it here.

FDA reviewing risk information in drug advertising

FDA said it is considering changes to requirements for communicating risk information in direct-to-consumer advertisements for prescription drugs and biologics, and

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE